An initiative of IBA Proton Therapy
Campus your proton
therapy community
  • Resource center
  • Training
  • Events
  • About
  • Log in
  • Resource center
  • Training
  • Events
  • About
  • Log in
An initiative of IBA Proton Therapy

Your results for

Filter by

Filter by
Results

Filter by

Content type
  • Event - Do not use (0)
  • Podcast (0)
  • Publications (9)
  • Training (0)
  • User case (1)
  • User meeting (0)
  • Webinar (0)
  • White paper (0)
Key content topics
Key audience
  • Newcomers (0)
Top cancer treatments
  • Brain and CNS (4)
  • Breast (3)
  • Gastro-intestinal (7)
  • Genito-urinary (2)
  • Gynecological (0)
  • Head and neck (23)
  • Hodgkin and Non-Hodgkin lymphoma (1)
  • Ocular (0)
  • Pediatric (1)
  • Reirradiation (1)
  • Sarcomas (0)
  • (-) Thoracic (10)
  • Reset filters
  • (-) IMPT
  • (-) Thoracic

Toxicity and Survival After IMPT Versus Passive Scattering PT for NSCLC.

10/10/2020
/ Publications
/
Toxicity
IMPT

This MD Anderson study compared toxicity profiles and clinical outcomes after IMPT versus PSPT for 139 patients with locally advanced NSCLC. Compared to the...

Proton Therapy in NSCLC

11/11/2018
/ Publications
/
IMPT
Immunotherapy

A review on PBT for NSCLC. The review pointed out that despite early results suggesting improvements or at least comparable outcomes, the most recent randomized...

Patterns of Local-Regional Failure after IMRT or Passive Scattering PT with Concurrent Chemotherapy for NSCLC.

08/08/2018
/ Publications
/
IMPT

Published in the Red Journal, this retrospective analysis by MD Anderson group reviewed 212 patients treated with IMRT and PT, most (152 [72%]) had no failure...

Advanced radiation techniques for locally advanced NSCLC: IMRT and proton therapy.

08/08/2018
/ Publications
/
IMPT
IMRT

This review article examined clinical outcomes data of IMRT and PBT for locally advanced NSCLC. This review pointed out that PBT is not considered the standard...

Reirradiation for locoregionally recurrent non-small cell lung cancer.

08/08/2018
/ Publications
/
Reirradiation
IMPT
Survival

In the context of definitive retreatment, increasing reRT dose can potentially improve OS and offer a chance of cure, particularly in patients with limited loco...

Clinical outcomes of intensity modulated proton therapy and concurrent chemotherapy in esophageal carcinoma (EC).

11/06/2017
/ Publications
/
IMPT
Chemotherapy
Toxicity

19 patients with EC treated with IMPT concurrently with chemotherapy. Clinical complete response was achieved in 84%.

The most common grade 3 acute toxicities...

High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial.

15/11/2022
/ Publications
/
IMPT
IMRT

This is a study protocol details a randomized trial taking place in Thailand with multiple centers comparing IMPT and IMRT for stage II–IVA squamous thoracic...

Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.

15/11/2022
/ Publications
/
IMPT
IMRT

163 consecutively treated patients with biopsy-proven, stage III NSCLC who received IMPT (n = 35, 21%) or IMRT (n = 128, 79%) were analyzed in this study...

Clinical experience from the first compact IMPT Proton Therapy Center: the advantages of treating in an open gantry environment

26/01/2018
/ Event
/
IMPT

The Willis-Knighton Health System, headquartered in Shreveport, Louisiana, is a not-for-profit community healthcare corporation with four general acute care...

Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.

28/03/2024
/ Publications
/
IMPT
IMRT
Toxicity

This study reported the incidence of lymphopenia in 271 stage III NSCLC patients treated with IMPT (n=71) vs IMRT (n=200) and concurrent chemotherapy. The...

Campus
Subscribe to our newsletter
Follow us on
  • Facebook
  • Linkedin
  • Twitter
  • Youtube
Contact us
  • About Campus
  • Resources
  • Training
  • Connect
  • IBA Worldwide
  • Back to IBA Proton Therapy
Life Science
  • Legal
  • Terms of Use
  • Privacy policy
  • Cookies policy
  • Manage cookies
  • Code of conduct

Cookies policy

If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.

Manage your cookie preferences

Respect for your privacy is still a priority for us at IBA.

Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.

Accept all cookies
Adapt my preferences
Cookies policies